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Abstract
The importance of the extracellular matrix (ECM) in 
contributing to structural, mechanical, functional and 
tissue-specific features in the body is well appreciated. 
While the ECM was previously considered to be a passive 
bystander, it is now evident that it plays active, dynamic 
and flexible roles in shaping cell survival, differentiation, 
migration and death to varying extents depending on 
the specific site in the body. Dendritic cells (DCs) are 
recognized as potent antigen presenting cells present in 
many tissues and in blood, continuously scrutinizing the 
microenvironment for antigens and mounting local and 
systemic host responses against harmful agents. DCs also 
play pivotal roles in maintaining homeostasis to harmless 
self-antigens, critical for preventing autoimmunity. What 
is less understood are the complex interactions between 
DCs and the ECM in maintaining this balance between 
steady-state tissue residence and DC activation during 
inflammation. DCs are finely tuned to inflammation-
induced variations in fragment length, accessible epitopes 
and post-translational modifications of individual ECM 
components and correspondingly interpret these changes 
appropriately by adjusting their profiles of cognate 
binding receptors and downstream immune activation. 
The successful design and composition of novel ECM-
based mimetics in regenerative medicine and other 
applications rely on our improved understanding of DC-
ECM interplay in homeostasis and the challenges involved 
in maintaining it.
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Core tip: The extracellular matrix (ECM) provides an 
essential framework for tissues in the body as well 
as actively orchestrates diverse cellular functions. Pro-
fessional antigen presenting cells namely dendritic cells 
(DCs) are uniquely positioned to distinguish between self 
and non-self and accordingly regulate systemic immunity 
or tolerance. DCs and the ECM participate in finely-tuned, 
dynamic exchanges that ultimately impact the equilibrium 
between steady-state DC tissue residence or DC-
instigated inflammation. To design biointeractive, ECM-
inspired implants for regenerative medicine applications 
that retain functionality and undergo successful integration 
long-term, it is critical to understand the challenges 
involved in maintaining DC-ECM immune homeostasis 
under normal conditions.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen presenting 
cells (APCs) that differentiate self from non-self and 
play crucial roles in determining the balance between 
tolerance and immunity. They were first discovered in 
mouse spleen by Steinman and Cohn[1] in a seminal 
paper published in 1973. Since this initial finding, the 
dogma that DC maturation is essential for the initiation 
of immunity has been well established. Immature DCs 
are typically distinguished by high levels of intracellular 
major histocompatibility complex class II (MHCII), low 
expression of adhesive and costimulatory receptors, 
strong endocytic, pinocytic and phagocytic abilities and 
weak capacities for T cell stimulation[2,3]. Immature DCs 
mount an immune surveillance program mediated in 
part by extracellular or cytoplasmic pattern recognition 
receptors (PRRs) expressed by DCs that identify evo­
lutionarily conserved pathogen associated molecular 
pattern motifs on bacteria, viruses and on other foreign 
bodies or endogenous damage-associated molecular 
patterns (DAMPs). These recognition events trigger 
their transformation from rounded immature DCs into 
terminally differentiated mature DCs with enhanced 
motility, that exhibit extended dendritic processes and 
upregulate expression of co-stimulatory (CD80, CD86), 
MHCII molecules and adhesion molecules which bind T 
cells[2]. Ingested antigens processed intracellularly and 
presented as spliced peptides are loaded on to MHC 
complexes on mature DCs. The interactions between 
MHC and T cell receptors [MHCI: cytotoxic T cells (Tc) 
and MHCII: helper T cell (TH) subsets] expressed on T 
cell surfaces drive antigen­specific cellular immunity. 
Notably, DCs are unique in their capacity to trigger T 
cell immunity. Taken together, DC­driven generation 
of cytokines, chemokines and other factors together 
orchestrate downstream host protective antigen­specific 
adaptive immune responses, as reviewed in[2]. DCs have 
three broad functions - mounting an immune response, 
maintaining immune tolerance and regulating immune 
memory, underscoring their critical roles in maintaining 
the balance between immunity and homeostasis[2]. 
This review discusses the growing body of evidence 
that the extracellular matrix (ECM) orchestrates DC 
interactions at different sites both in homeostasis and in 
inflammation. These interactions are highly complex and 
have many redundancies since DCs possess numerous 
receptors capable of binding the multicomponent ECM 
and are capable of upregulating and downregulating 
the expressions of PRRs in response to alterations in the 
ECM, thereby making it essential to better understand 
this interchange. Many questions remain incompletely 
elucidated: Why DCs are selective in terms of residing 
in certain tissues but not in others. For instance, what 
roles do tissue specific cytokines, chemokines and other 
factors associated with and released by the ECM play 
in regulating DC behaviour? To what extent are other 
tissue resident cells responsible for maintaining DC 
homeostasis, e.g., hepatic stellate cells (HSCs) in the 
liver[4], epithelial cells in intestine[5], or keratinocytes in 
skin[6]. Finally, how do alterations in the ECM affect the 
DC steady­state and are these alterations reversible? 
DC sUbseTs
Over the last few decades several groups have con­
tributed to the large body of work performed in chara-
cterizing DCs present in tissues and in blood and their in 
vitro generated counterparts. DCs are identified by the 
expression of MHCII and costimulatory markers, and 
the absence of lineage markers such as CD3 (T cell), 
CD14 (monocyte), CD19 (B cell), CD56 (natural killer 
cell) or CD66b (granulocyte)[2]. DCs are described as 
two types: Conventional DCs (cDCs) and plasmacytoid 
DCs (pDCs). The cDCs are a principal DC subset and 
are sub­divided into migratory and non­migratory. 
Migratory DCs arise from the tissues and reach secon-
dary lymphoid organs (SLO) via the lymphatics. Tissue 
resident conventional migratory DCs are broadly classi­
fied as CD103+ CD11b− and CD11b+ cDCs and have 
been described in intestine, liver, lung, kidney and skin 
as reviewed in[7,8]. The specific locations and roles of 
the different DC subsets vary in different tissues. For 
instance, lung DC subsets include migratory CD103+ 
CD11chigh CD11b- DCs in the intra-epithelial network, 
CD103- CD11chigh CD11b+ DCs in the lamina propria 
(LP) and non­conventional pDCs[8]. Intestinal DCs in 
Peyer’s Patches (PP), LP and mesenteric lymph nodes 
exhibit varied expression of CD103 and CX3CR1 of 
which migratory, conventional CD103+ DCs have been 
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assigned both immunogenic and tolerogenic roles[8]. 
Liver DCs consist of CD11c+ B220- DCs (further divided 
into CD103+ and CD103-), both linked to regulatory T 
cells (Treg) induction as reviewed in[8] and CD11c+ B220+ 
pDCs, the latter playing a role in maintaining steady 
state tolerance and the resolution of inflammation after 
liver injury[8]. Kidney DCs comprise CX3CR1+ CD11b+ 
DCs, CX3CR1+ CD11b- DCs and CD103+ DCs, while 
CD103+ cells are thought to play a tolerogenic role as 
opposed to other subsets as reviewed in[8]. Skin DCs 
include dermal DCs which are Langerin+ (CD207+) 
CD103+ DCs and are categorized as cDCs with bone 
marrow precursors, as well as Langerin- CD103- DCs 
(with unknown precursors)[8]. 
Conventional DCs also include lymphoid DCs that 
are distinct from myeloid DCs, lack expression of 
CD11b, CD13, CD14, and CD33 and are derived from 
precursors that have the ability to differentiate into 
T cells and NK cells as reported in[3] as opposed to 
monocyte/macrophage lineages[9]. While cDCs sample 
tissue antigens and migrate to present the processed 
peptide(s) to T cells in LNs, in contrast, non-migratory 
cDCs previously considered as “lymphoid” DCs reside in 
thymus, spleen, LNs or PP[3,10]. Lymphoid DCs include 
CD4-CD8α+ DCs that cross present antigen to CD8+T 
cells, while CD4+CD8α- DCs in spleen or CD4-CD8α- DCs 
in mucosal associated lymphoid tissue, activate CD4+ 
T cells. Non-migratory lymphoid DCs regulate thymic 
negative selection, drive TH2 responses in humans and 
stimulate regulatory responses overall[3].
The pDCs are found mostly in lymphoid tissues 
and secrete IFN-α upon exposure to viral antigens. 
Phenotypically, pDCs, the second principal DC subset 
express CD45RA, CD123, CD303 and CD304 as well 
as low levels of MHCII, costimulatory molecules and 
CD11c, while myeloid DCs express CD11c, CD13, CD33 
and CD11b[11]. The pDCs are highly secretory, exhibit 
plasma cell-like morphologies and display properties 
of both cDCs and lymphocytes. Importantly, pDCs 
express endosomal TLR7 and TLR9 that detect viral 
single stranded RNA and unmethylated CpG-containing 
DNA and respond by rapid and substantial production 
of type Ⅰ IFN (IFN-α/β)[12]. Plasmacytoid DCs start in 
bone marrow and enter lymphoid tissues where they 
mainly reside, through blood[7]. Plasmacytoid DCs are 
important for mediating differentiation of B cells to 
plasma cells for antibody production and have been 
linked to immunogenic and tolerogenic responses in the 
liver and lung as reviewed in[8]. Most DCs [apart from 
yolk sac derived ­ Langerhans cells (LCs)] are generated 
in bone marrow from myeloid progenitor cells[13] with 
some in situ proliferation in spleen. Another class of 
non­conventional DCs namely monocyte­derived “infla­
mmatory” DCs have been detected in the skin and 
kidneys and intestine and have been implicated in the 
progression of inflammation in colitis and as CD103- 
CX3CR1+ DCs in maintaining gut homeostasis. In the 
lung, CD103- CD11chigh CD11b+ DCs play crucial roles 
in reacting to allergens and triggering TH2-mediated 
immunity. Finally, self-renewing DC-like cells such 
as slow turnover LCs and microglia are specialized 
dendritiform cells derived from the yolk sac and reside 
in the squamous epithelium and in CNS parenchyma 
respectively and mediate tolerance in the resting 
states[8,11]. 
It is clear that DCs are not narrowly defined as 
a single type of cell but instead represent a diverse 
assortment of cells derived from different lineages[10,14-17]. 
The generally accepted theory is that hematopoietic DC 
progenitors from the bone marrow circulate through 
the body and are receptive to specific combinations 
of cytokines and signals, resulting in DC subsets with 
specialized homing properties and roles. In vitro DCs 
have been generated from CD14+ monocytes in blood 
and CD34+ bone marrow precursors[2]. “Classical” 
myeloid DCs have been generated from myeloid com­
mitted CD34+ progenitor cells and monocytes treated 
with granulocyte macrophage colony stimulating factor 
(GM-CSF) and tumour necrosis factor-α (TNF-α) ± 
interleukin-4 (IL-4) in vitro[7,8,11,18,19]. Myeloid DCs regu-
late responses of CD4 and CD8 T cells and are involved 
in B cell differentiation into plasma cells. In addition, 
CD34+, CD14- cells differentiate into LCs in the presence 
of transforming growth factor-β (TGF-β)[7,8,11,18,19]. Also, 
lymphoid committed CD34+ cells become pDCs in the 
presence of IL-3[20]. Myeloid DCs are sometimes referred 
to as DC1 and express toll-like receptor 2 (TLR2), TLR3, 
TLR4, TLR7 and activate naïve T cells along TH1, TH2 
pathways[7,8,11,18,19]. In contrast, lymphoid DCs or DC2 
express TLR7 and TLR 9 and secrete IFN-α in response 
to invading viruses. Notably, high numbers of DCs have 
been generated in mice and in humans by recurrent 
injections with hematopoietin flt-3L, thought to act on 
DC precursors in the bone marrow[2,21,22].
Interestingly however, when tissue residence is 
discussed there is little reference to how the tissue 
might affect or even permit the DCs to migrate into 
tissue matrices and egress from it via the lymphatics. 
Furthermore, changes in the tissue which occur during 
inflammation will affect not only the resident DCs but 
also newly recruited DCs. For instance, the retina in 
normal mice has a small population of MHCII+ 33D1+ 
DCs located mainly at the periphery while tissue resident 
microglia are macrophage­like cells. However, during 
inflammation, e.g., uveoretinitis, there is a marked 
increase in the numbers of antigen-presenting cDCs[23]. 
Microglia mostly maintain tolerance in non-inflamed 
retina but can become activated during degenerative 
disease such as age-related macular degeneration 
(AMD) or inherited retinal degeneration[24]. Dysregulated 
clearance/accumulation of debris result in microglial 
activation accompanied by elevated production of pro­
inflammatory chemokines and cytokines. Similarly, 
bone and cartilage do not have DCs under steady state 
conditions[25], although activated DCs can trigger cartil­
age degradation by producing TNF-α. It is not clear 
why certain tissues restrict DCs from being present in 
steady state or why others permit their entry. It would 
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expression of ECM factors in different physiological 
states (foetal, neonatal, adult)[28,36]. Importantly, 
ECM interactions with cytokines including fibroblast 
growth factor, TGF-β, interferon-γ (IFN-γ), macrophage 
inflammatory protein-1β, ILs or TNF-α and enzymes 
such as heparanase, urokinase-type plasminogen 
activator, elastase or matrix metalloproteinases (MMP) 
regulate the increase or decrease of inflammation at 
sites of tissue injury[37]. Blocking heparanase activity 
helps counteract early ECM degradation by controlling 
early inflammation[29]. Heparan sulfate in ECM binds 
chemokines and cytokines such as IL-2 and IFN-γ in 
steady state and when freely available, IL­2 triggers 
immune responses underscoring the point that ECM 
channels the host response towards or away from 
homeostasis[29]. Taken together, the picture emerging 
is that contrary to earlier concepts, the ECM is not a 
passive bystander but actively participates in the overall 
immune response. Indeed, the notion that the tissue 
regulates the immune response has been proposed by 
Matzinger[38] although precisely how awaits discovery. 
At the microenvironmental level, the matrix is dynamic 
and attuned to the stage of the immune/inflammatory 
response, prompting factors that are pro­inflammatory 
early on in the response to have anti­inflammatory 
effects during wound resolution[29].
TIssUe maTRICes aND DCs IN 
hOmeOsTasIs
DCs occupy diverse matrices in different tissues. The 
matrices assist in preserving DC tolerance through 
unique interactions and support their immune survei­
llance program. Some of these examples have been 
briefly reviewed here namely for skin, intestine, liver, 
retina, cornea and spleen. Although this is not a 
comprehensive list, immune privilege at different sites 
has been exhaustively reviewed elsewhere[39]. Long-
lived LCs reside in skin epidermis (Figure 1) and 
maintain homeostasis by forming E-cadherin junctions 
with keratinocytes and by TGF-β mediated events via 
suppression of pro-inflammatory factors IL-1, and 
TNF-α[6,40,41]. Resting epidermal LCs in normal adult 
human skin importantly have the capacity to preserve 
immune homeostasis by stimulating tolerogenic skin 
resident Treg responses to self-antigens and can also elicit 
activation of Teff cells in response to foreign pathogens[42]. 
Interestingly, CD1a+ and Birbeck granule expressing LCs 
also express neuronal receptors and communications 
between LCs and nerves suggest bidirectional signalling 
towards sustaining homeostasis[43]. Homeostasis and 
development of specialized DCs such as LCs and mic­
roglia rely on IL-34 secreted by epidermal keratino-
cytes and brain neurons respectively[44] Neuropeptides 
have been shown capable of regulating DC function. 
Interestingly, the neurotransmitter neurokinin A activ­
ates bone marrow­derived DCs to drive type 1 immune 
responses by targeting the neurokinin-2 receptor on 
be fascinating to gain an understanding of what the 
microenvironmental cues provided by the ECM towards 
this are as well as how these signals are altered in 
pathological conditions to pave the way for DC infiltration 
and subsequent immune responses. 
FUNCTIONal DIChOTOmy OF eCm 
It has been well established that the ECM plays critical 
roles in regulating cellular differentiation, survival, shape 
and function including adhesion, motility, apoptosis 
and tissue specific alignment[26,27]. The ECM is a three 
dimensional mixture of triple helical collagens, com-
plex proteoglycans composed of glycosaminoglycans 
covalently linked to protein, glycoproteins, proteases, 
growth factors and cytokines that respond actively to 
microenvironmental conditions[28,29]. Notably, dysre-
gulation or mutations in the ECM have been linked to 
developmental, degenerative, malignant, and pathological 
states such as cancer and inflammatory arthritis[26], while 
oxidative impairment of ECM components by enzymatic 
or non-enzymatic pathways has been associated with 
progression of kidney disease, lung disease, arthritis, and 
chronic inflammation[30]. Protein fragmentation has been 
proposed to form site­specific focusses for free radicals 
and reactive species as suggested in this review[31].
Remarkably, the ECM displays functional dichotomy. 
Besides forming a supporting mesh to stabilize cells, 
the ECM plays active roles in regulating normal or 
pathological states of inflammatory cells[27]. Degradation 
of intact steady state high molecular weight proteins 
to low molecular weight fragments has been directly 
linked to initiating and contributing to the progression of 
inflammation as demonstrated for major constituents of 
the ECM such as collagen, elastin, laminin, hyaluronan 
(HA) or fibronectin, based on their effects on neutr-
ophils, monocytes, macrophages[27,32-34]. In chronic lung 
neutrophil-mediated diseases that affect the matrix 
such as chronic obstructive pulmonary disease or in 
cystic fibrosis, evidence suggests that the products 
of protease degradation of matrix proteins (elastin, 
collagen fragments) are active triggers of inflammation 
(chemotactic for neutrophils)[35]. Interestingly, the 
degradation of interstitial matrix components such as 
collagen can induce peripheral blood mononuclear cells 
(PBMC) activation via IL-1β production, and to different 
extents depending on the nature of the collagen pep-
tide[33]. In homeostasis, matrix components such as 
fibronectin play essential roles in mediating tissue cell 
adhesion and stabilize the ECM by interactions with 
fibrinogen. In contrast, fibronectin fragments detected 
in synovial fluid in rheumatoid arthritis (RA) display pro­
inflammatory characteristics such as enhanced mono-
cyte chemoattraction, phagocytosis of polymorphonuclear 
leukocytes and complement engagement as compared 
to intact fibronectin[34]. Similarly, ECM components can 
play dual roles, one during cardiac development and 
second in healthy recovery or persistent heart failure 
after myocardial infarction as indicated by the diverse 
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DCs[45], while other neuropeptides such as Substance P, 
calcitonin gene-related peptide (CGRP) and somatostatin 
importantly can be secreted by DCs and regulate T cell 
activation[46]. Further, signalling via type 1 CGRP receptor 
on human DCs downregulates expression of MHCII 
and CD86 as well as decreases DC-associated T cell 
proliferation[47].
Similar to the skin, intestinal mucosa represent lar-
ge surface areas exposed to the outside environment. 
It is therefore critical to maintain DC tolerance under 
steady state conditions. Intestinal CD103+ CD11b+ 
migratory DCs in LP, PP, gut-associated lymphoid tissues 
or solitary intestinal lymphoid tissue are key regulators 
of homeostasis[48] and are capable of inducing anti-
inflammatory Treg differentiation[5]. Also, CX3CR1+ 
and CD103+ mucosal DCs in the LP are important in 
maintaining gut immune homeostasis[49]. Furthermore, 
DCs in PP and mucosal DCs in LP are involved in gene­
rating oral tolerance to collagen Ⅱ in collagen-induced 
arthritis models, mediated by TGF-β, Tregs and tipping 
the balance towards TH2 cytokines (IL-4)[50]. 
Liver resident professional and non­professional APCs 
including Kupffer cells (KCs), liver sinusoidal endothelial 
cells and DCs are crucial in maintaining hepatic tolerance 
under non-inflammatory conditions[51,52]. The HSCs 
located in perisinusoidal spaces of the liver have the 
ability to present antigen under tolerogenic conditions 
and exhibit cytoplasmic interactions with a broad range 
of functionally diverse cells such as hepatocytes, sinu­
soidal endothelial cells and KCs[4]. Specifically, HSCs co­
exist with murine liver DCs in vivo under homeostatic 
conditions and were shown to downregulate DC activation 
via tryptophan-catabolizing enzyme indoleamine-
2,3-dioxygenase expression, towards establishing an 
anti-inflammatory phenotype[4]. Specifically, resident 
immature DCs operating in the microenvironment of 
anti­inflammatory IL­10 and TGF­β are tolerogenic and 
block the activation of liver penetrating lymphocytes via 
interactions of cytotoxic T lymphocyte associated antigen 
receptor­4 and PD­1, both of which are potent negative 
regulators of T cells[51]. 
The transparent, avascular cornea at the anterior 
of the eye is comprised of the epithelium, the highly 
stratified layers of collagen typesⅠ and Ⅲ that form the 
stroma and the innermost endothelial layer. Towards 
sustaining homeostasis in the normal healthy state, 
CD11b+ CD11c+ DCs present in the stroma act as 
sentinels, maintaining an MHCIIlow CD80low CD86low 
immature phenotype in the centre of corneas vs at the 
periphery where immature and mature DCs coexist[53,54]. 
Following inflammation, infection or corneal trauma, 
resident B220+ CD11clow pDCs, CD34+ MHCII myeloid 
precursors and CD11b+CD11c- macrophages, as well 
as infiltrating DCs recruited from the bone marrow 
permeate the corneal collagen matrix as part of the 
protective response[55-57].
In the spleen, the largest secondary lymphoid organ, 
several resident DC populations including lymphoid 
DCs, myeloid DCs and pDCs have been identified in 
both humans[58] and mice[59]. However, relatively little 
is understood about the complex interactions between 
the matrix components and DCs occupying different 
splenic zones that are responsible for the crucial task of 
maintaining tolerance to self-components. Interestingly, 
splenic stroma has been shown capable of supporting 
hematopoiesis of dendritic-like cells from splenic or 
bone marrow precursors[60]. Within the bone marrow, 
specialized tissue microenvironments or niches crucial for 
homeostasis of resident hematopoietic stem cell DC pro-
genitors have been described at vascular sites mediated 
by associations with endothelial cells or at osteoblast 
sites[61]. Furthermore, while cellular mechanisms re-
sponsible for DC tolerance in certain tissues have been 
elucidated, the specific nature of the ECM ligands 
and counterparts that form an important part of this 
“homeostasis handshake” remain poorly characterized.
Markedly, DCs are absent or at least their presence 
is debated in certain tissues such as the brain[62], while 
others have contradicted this finding[63]. It is important 
to mention that isolations of brain DCs have been 
contaminated with DCs from the meninges which are 
themselves very rich in DCs[64], analogous to the retina 
which has few, if any DCs as opposed to the uvea which 
is abundantly populated with DCs. Under steady-state 
conditions normal brain parenchyma was found to 
have resident CD11c+ MHCIIneg ramified cells, possibly 
differentiated from microglia[63]. Also, brain resident DCs 
could be removed and differentiated into immature DCs 
with GM-CSF and to mature DCs with CD40 ligation 
as shown in[65]. It is important to elucidate how DCs 
maintain homeostasis and also why they are absent 
in bone, cartilage and other tissues, yet these tissues 
are flooded with DCs during inflammation. What are 
the cues from the ECM that keeps DCs away during 
homeostasis? How does the ECM contribute towards 
this diversion/chemorepulsion event? Or do DCs gain 
entry but then undergo apoptosis? Finally, how is this 
phenomenon relevant to enhancing the immunocom­
patibility of artificial stroma utilized in regenerative 
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Figure 1  Murine Langerhans cells in ear skin reside in the epidermis, 
stained here for major histocompatibility complex class Ⅱ (green). 
Reprinted from Jakob T, Ring J, Udey MC. Multistep navigation of Langerhans/
dendritic cells in and out of the skin. J Allergy Clin Immunol 2001; 108: 688-696 
Copyright (2001), with permission from Elsevier.
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medicine?
IT wORks bOTh ways: DC 
mODUlaTION OF maTRICes
Communication between DCs and the ECM is bi-
directional. The DCs signal out to the ECM and actively 
modulate the matrix which affects their ability to 
migrate, adhere, traffic into lymphatics, or cross the 
vascular endothelium. Specifically, epidermal LCs 
migrate towards skin-draining LNs after antigen enco-
unter, a complex transmigration event mediated by C­C 
chemokine receptor type 7 (CCR7), selectins, integrins 
and MMP activity to cleave ECM components (Figure 
2)[6,40,41]. In the LNs, LCs present antigens in the context 
of self/non­self to T cells to drive tolerance or immunity, 
as seen in TH2­driven atopic dermatitis[66,67]. Markedly, in 
heparanase deficient mice that are incapable of cleaving 
heparan sulfate in the ECM and on cell surfaces, the loss 
of heparanase results in critical defects in facilitating DC 
migration from skin to lymphatics. Intriguingly, immature 
DCs in these mice transition to mature DCs and appear 
more activated. Increased DC activation is possibly due 
to the compensatory elevation of CCR7 expression and 
CCR7­CCL19­driven DC activation[68]. Furthermore, 
DCs co-cultured with fibroblasts in the presence of 
TNF-α/IL-1β enhanced MMP-9 expression on DCs, 
important for DC migration via degradation of collagen 
type Ⅳ in basement membranes[6], underscoring the 
important role played by the ECM in maintaining DC 
homeostasis and controlling DC localization within 
tissue. Tissue migratory cDCs display heterogeneity 
depending on their microanatomical location. For 
instance skin epidermal migratory LCs are distinct from 
dermal DC subsets (Langerin+CD11blow, Langerin-
CD11b-, and Langerin-CD11blow) and display differential 
migratory characteristics depending on the nature of the 
antigen[69]. Following skin infection with HSV, epidermal 
LCs migrated swiftly away from the epidermis, likely 
towards skin draining LNs in contrast to dermal DCs 
which collected in the dermis together with monocyte-
derived DCs[70]. On the other hand, skin painting with 
contact sensitizing substances resulted in differential 
migration kinetics within different dermal DC subsets 
and as compared to LCs, suggesting that dermal DCs 
arrive earlier in cutaneous LNs and are involved in the 
early response to skin immunization[71]. This observation 
is supported by another study that demonstrated a 
vital role for tissue migratory dermal DCs rather than 
migratory LCs in response to contact hypersensitivity 
induced by 2,4­dinitro­1­fluorobenzene in terms of their 
abilities to elicit antigen­specific T cell proliferation. Taken 
together, these studies highlight the exquisite complexity 
that tissue migratory DCs demonstrate in their direction 
of response, migration kinetics and role depending on 
the specific properties of the matrix that they occupy. 
In other words, the DC subset that migrate initially to 
the site of an insult and therefore help shape the overall 
adaptive response may be profoundly impacted by the 
anatomical and microenvironmental location of the 
injury and the resident DC populations present there.
maJOR eCm COmPONeNTs ImPINGING 
ON DC
Individual constituents of the ECM have been associated 
with differential impacts on inflammation and immunity. 
Distinct contributions of the various classes of ECM 
macromolecules have been reviewed in this section 
with special emphasis on their unique interactions with 
DCs to highlight how the specific biology, site in the 
body, phase of response, form (soluble or particulate), 
fragment length, post-translational adaptations and 
enzymatic modifications may vary in healthy vs pat-
hological conditions (Table 1). While by no means a 
comprehensive list, we highlight that ECM components 
are crucial factors and play distinct roles in directing 
innate/adaptive responses, focusing on DC/cellular/
humoral-orchestrated downstream homeostasis or 
inflammatory consequences. 
Collagen
Collagens represent a major component of the ECM 
and connective tissue with characteristic Gly­Pro­X 
repeats, providing support and tensile strength[72]. 
Collagen type Ⅰ (skin, tendon, bone, interstitial tissues, 
ligaments, cornea), type Ⅱ (cartilage, vitreous humour) 
and type Ⅲ (skin, muscle, blood vessels) account for 
the majority of collagens present in the body[72]. While 
collagen types Ⅰ, Ⅱ and Ⅲ are present as covalently 
crosslinked fibrils, notably, type Ⅳ collagen forms a two 
dimensional reticulum (basal laminaes)[73]. The type and 
form (soluble or particulate) of collagen appear to be 
important determinants of their abilities to stimulate DC 
activation. Soluble collagen typesⅠ, Ⅱ, Ⅲ coated onto 
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Figure 2  Mature skin dendritic cells egress via  lymphatics that display 
secondary lymphoid tissue chemokine (SLC/CCL21) constitutively. Shown 
here are two mature DC expressing MHC class Ⅱ (green) located within a 
lymphatic vessel that presents SLC (red). Reprinted from Jakob T, Ring J, Udey 
MC. Multistep navigation of Langerhans/dendritic cells in and out of the skin. 
J Allergy Clin Immunol 2001; 108: 688-696 Copyright (2001), with permission 
from Elsevier. Courtesy of Saeki H and Hwang S, National Cancer Institute, 
Bethesda, MD.
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dishes activated murine/human BMDCs and resulted 
in elevated costimulatory receptor expression, pro­
inflammatory cytokine secretion and allostimulatory 
capacities[74-76], demonstrating that ECM components 
can trigger DC activation locally. In contrast, extracted 
dermal hydrogels composed of basement membrane 
constituents such as particulate collagen type Ⅳ, 
collagen type Ⅶ and laminin β3 improved dermal wound 
healing in a rodent model and mitigated granulation 
tissue thickness by assisting with wound contraction[77]. 
Furthermore, in a study comparing the effects of 
individual matrix components on DC maturation, 
DCs cultured on plates coated with ECM components 
fibronectin, collagen, gelatin, or on poly-lysine or 
polystyrene surfaces were observed to upregulate CD80, 
MHCII in the presence of pro-inflammatory factors. 
Interestingly however, on Matrigel (collagen type Ⅳ, 
laminin, entactin, heparan sulfate proteoglycans)-coated 
surfaces, the ECM components were able to inhibit DC 
maturation even in the presence of activating factors[78], 
suggesting that gelatinous Matrigel derived from murine 
tumour stroma and mimicking basement membranes 
promotes DC tolerance to maintain homeostasis under 
normal conditions. 
Glycoproteins - fibronectin, vitronectin, laminin and 
fibrillin
Glycoprotein constituents of ECM play well defined 
roles during inflammation. In injury, fibronectin draws 
cells towards repopulating the wound by exploiting cell 
surface integrins, while laminin helps in the formation of 
blood vessels[72]. Interestingly, fibronectin and laminin 
have been implicated in inhibiting DC maturation. 
Specifically, human monocyte­derived DCs cultured in 
the presence of pre-adsorbed fibronectin and laminin 
retained a less mature phenotype with enhanced 
endocytic capacities (Figure 3)[79]. On the other hand, 
modified presentation of Arg-Gly-Asp (RGD) integrin-
binding sequence of the ECM glycoprotein fibrillin in 
microfibrils disrupted murine pDC adherence and in-
creased its activation (IFN­α, IL-6), plasma cell and B 
cell accretion and autoantibody secretion, skewing of 
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Tissue Location Resident DC in naïve tissue Resident associated cells/
naïve tissue
Stromal/cellular interactions in immune 
homeostasis
Ref.
Skin Epidermis Cd1a+ Langerin+ Langerhans cells 
expressing Birbeck granules
Keratinocytes E-cadherin junctions with 
keratinocytes, TGF-β production, 
tolerogenic Treg responses
[6, 40-42] 
Dermis CD1c+ DC-SIGN+ DEC205+ dermal 
DC subsets (Langerin+ CD11blow, 
Langerin-CD11b-, and Langerin-
CD11blow)
To be elucidated 
(presumed dermal matrix, 
fibroblasts)
Pluripotent dermal DC may present 
antigen, migrate or reside in tissue 
depending on local interactions 
[69, 144]
Intestinal 
mucosa
LP, Peyer’s patches, 
GALT,  SILT
CD103+CD11b+ or CD103+ CD11b-
migratory DC, CD103+Sirpα- DC, 
pDC, CX3CR1+ DC
Macrophages, B cells Maintain immune homeostasis, induce 
Treg differentiation, oral tolerance 
(TGF-β, Treg, TH2 factors)
[5, 48-50, 
145, 146]
Gut: Retinoic acid, TH17 cells
LP: indoleamine 2,3-dioxygenase
CD83 on DC regulates mucosal 
tolerance
Liver Portal tracts, interstitial 
DC
CD103+DC, CD103-DC, CD103-
CD11b+DC, CD141+ DC (high in 
healthy liver)
Hepatic stellate cells, 
sinusoidal endothelial 
cells, Kupffer cells, 
hepatocytes
Inhibit DC activation (indoleamine-2,3-
dioxygenase expression), repress T cell 
activation (IL-10, TGF-β) via CTLA-4, 
PD-1
[4, 51, 
52,147,148]
Cornea Central/peripheral 
corneal stroma
CD11b+ CD11c+ DC, B220+ CD11clo 
pDC, CD34+ MHCII myeloid 
precursors
Stromal Collagen Ⅰ, 
CD11b+ CD11c- 
macrophages, keratocytes
Maintain MHCIIlow CD80low CD86low 
phenotype under normal conditions
[54-57]
Spleen Marginal zones Lymphoid, myeloid and pDC Macrophages, T cells, B 
cells (zone dependant)
To be elucidated [58-60]
Bone 
marrow
Osteoblastic or vascular 
niches
Resident hematopoietic stem cell DC 
progenitors
Osteoblasts, stromal cells 
and sinusoidal endothelial 
cells 
- [61]
Retina Peripheral margins and 
juxtapapillary areas
Presence of DCs is debated. Likely migrated in from 
choroid, ciliary body and 
meninges
Perivasulcar - around retinal venules 
(initial site of immune disruption), but 
not arterioles.
[149]
Few MHCII+ 33D1+ DC observed in 
naïve brain
Brain Regions of synaptic 
plasticity and 
neurogenesis
Presence of DCs is debated. - - [62,63,150]
Brain-derived CD11c+ DC
Bone/
cartilage/
vitreous
Not detected - - - -
Table 1  Dendritic cells and the maintenance of homeostasis in different tissues
DC: Dendritic cell; TGF-β: Transforming growth factor-β; LP: Lamina propria; GALT: Gut-associated lymphoid tissues; SILT: Solitary intestinal lymphoid 
tissue; MHCII: Major histocompatibility complex class Ⅱ; IL: Interleukin-4.
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TH subsets and ultimately enhanced dermal fibrosis, 
showing a role for fibrillin in instigating pro­inflammatory, 
pro­fibrotic programmes[80]. 
Non-proteoglycan polysaccharides
HA: HA a copolymer of GlcNAc and GlcUA plays dual 
roles both as supporting meshwork of lymphatics as 
well as that of a potent danger signal, based on the frag-
ment length[81]. Breakdown of long glycosaminoglycan 
HA resulting in the formation of small HA fragments 
activated skin DCs. Higher serum and lymphatic HA 
levels have been associated with reduced DC maturation 
and feeble tumour responses correlating to higher HA 
in tumour ECM[82]. Hyaluronic acid is a significant non­
immunogenic component of healthy ECM linked to 
wound healing, inhibition of inflammation and angio-
genesis. Hyaluronic acid hydrogels enhanced healing 
after myocardial infarction in rats by decreasing collagen 
production and increasing vascular endothelial growth 
factor levels[83]. 
Modulators: Periostin plays an anti-inflammatory 
role in IgE­mediated airway hyperresponsiveness and 
allergy via upregulating active TGF­β and therefore 
inducing differentiation of Tregs[84]. Tenascin C is an ECM 
glycoprotein not normally detectable in healthy adult 
tissues but is present in pathological conditions such as 
arthritis[85] and myocarditis[86]. In tumours, tenascin C 
has been implicated in epithelial mesenchymal transition 
and migration of cancer cells[87]. Secreted protein acidic 
and rich in cysteine is a Ca2+ binding matrix glycoprotein 
involved in organization of germinal centres of LNs 
and essential for follicular DCs to receive necessary 
cues to induce TH17 differentiation as shown in a model 
of experimental autoimmune encephalomyelitis[88]. 
Thrombospondin 1­DC axis is a negative regulator of 
inflammation associated with elevated levels of anti­
inflammatory mediators (PGE-2, TGF-β). It is critical 
towards maintaining homeostasis and serves to resolve 
inflammation during wound healing[89].
MMPs
In injury, enzymes are involved in matrix turnover and 
remodelling, needed for cell entry and egress and pro-
liferation, vasculogenesis and angiogenesis[72]. Tumour 
enlargement and dissemination involve interplay bet­
ween tumours, immune cells and ECM. Active MMP­2 
acts as an endogenous anti­inflammatory mediator as 
evidenced by anti­inflammatory TH2 profile of MMP-2-
expressing CD4+ T cells that infiltrate tumours and the 
roles of MMP­expressing DCs in inducing this profile via 
OX40L and inhibition of IL­12p70 production[90,91]. 
Post-translational modifications of ECM components 
and effects on DC homeostasis
Post­translational modifications including glycation, carba­
mylation and citrullination have implication in diabetes, 
kidney fibrosis and inflammatory conditions such as 
rheumatoid arthritis respectively[92], via interactions with 
DC C- type lectin receptors (CLRs), a class of PRRs[2]. 
Alterations of the ECM are strongly linked to altered 
ligand binding and cellular interactions[93]. Inhibition of 
terminal fucosylation alters macrophage phenotype from 
pro­ to anti­inflammatory, demonstrating how immune 
homeostasis can be compromised by altered glyco-
sylations of ECM components[94]. Altered fucosylation 
and exposure of glycans normally “buried” on serum 
IgG have been implicated in systemic lupus erythemato­
sus progression[95], while changes in sialylations may 
transform it from being pro- to anti-inflammatory[96]. 
Interestingly, mucosal surfaces of the human female 
reproductive tract display glycation patterns analogous 
to those seen on metastatic cells or on efficacious 
pathogens in order to promote anti-inflammatory 
responses for survival of placenta and human sperm[97], 
reinforcing the observations that host proteins can be 
altered to present tolerizing or activating glycosylation 
patterns as reviewed in[98].
DC ReCePTORs FOR eCm
DCs express many receptors which interact with tissue 
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Figure 3  Scanning electron microscope images demonstrate that dendritic cells cultured on fibronectin or laminin for 48 h exhibit widely differential 
morphologies. Taken in part from García-Nieto S, Johal RK, Shakesheff KM, Emara M, Royer PJ, Chau DY, Shakib F, Ghaemmaghami AM. Laminin and fibronectin 
treatment leads to generation of dendritic cells with superior endocytic capacity. PLoS One 2010; 5: e10123. Copyright (2011), published under the Creative Commons 
Attribution (CC BY) license. FN: Fibronectin; LAM: Laminin.
× 2.000 × 1.600 × 2.500
10 μm 10 μm 10 μm
CTRL FN LAM
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or matrix components during homeostasis as well 
as with their breakdown products[78], some of which 
have been reviewed here and summarized in Table 2. 
Immature DCs express adhesion complexes to bind 
different structural ECM components: CD49a/CD29 and 
CD49b/CD29 to collagen and laminin; CD49c/CD29 
to collagen, laminin, fibronectin and thrombospondin; 
CD49d/CD29 and CD49e/CD29 to fibronectin; CD49f/
CD29 to laminin; CD41, CD51 and CD61 to fibrino-
gen, fibronectin, vitronectin and thrombospondin[78]. 
Besides expressing adhesion molecules to direct their 
migration and localization within tissues, DCs express 
extracellular and cytoplasmic PRRs such as TLRs, 
RIG-I-like receptors (RLRs) and NOD-like receptors 
(NLRs) that respond to pathogens[99,100]. Major PRRs 
such as TLRs bind bacterial and viral nucleic acids, 
lipopetides, and lipopolysaccharide and initiate signalling 
cascades triggering DC maturation[101]. Cytoplasmic 
RLRs recognize bacterial and viral nucleic acids while 
NLRs such as NOD1 and NOD2 bind bacterial peptido-
glycans[102]. Endocytic scavenger receptors recognize 
modified and unmodified lipoproteins[103].
Another class of PRRs, endocytic CLRs bind glyc-
osylated moieties in a Ca2+ dependant manner, and 
internalize and present both self and non-self on MHC 
molecules[104,105]. CLRs recognise glycations on ECM 
constituents - N-linked glycans present on glycoproteins 
as well as O-linked glycans on collagens[105]. Importantly, 
antigen uptake by CLRs resulting in TLR ligation results 
in the generation of antigen-specific immunity, while 
in contrast, CLR-mediated recognition alone facilitates 
homeostasis and tolerance to tissue antigens, as 
discussed in this review[105]. There is growing evidence 
that CLRs play significant roles in regulating immune 
tolerance in the gut[106]. Dectin-1 and galectin-3 main-
tain tolerance to gut mucus by repression of NF-κB[107]. 
Tolerogenic DCs recognize GalNAc on tumours by 
MGL (macrophage galactose/N-acetylgalactosamine-
specific C­type lectin) binding[105] and mannose receptor 
expressed by DCs has been implicated in maintaining 
immune homeostasis[108]. Furthermore, MGL1+ and 
MGL2+ cells were detected in various tissues under 
normal conditions suggesting that they play an active 
role in tightly controlling DC homeostasis in tissues regu-
larly exposed to antigens including thymus, intestine, 
stomach, trachea and skin[109]. Modified glycosylation 
patterns alter CLR binding and contribute towards 
immune evasion by impacting CLR­TLR cross talk[105].
“Homeostatic danger signals” were defined in a recent 
review as disruptions in tissue steady­state that stimulate 
DC activation, typically occurring during inflammation[110]. 
Endogenous DAMPs released or activated during injury or 
surgical trauma include degraded ECM constituents such 
as fibronectin, fibrinogen, HA[111,112] heparan sulfate[113], 
biglycan[114,115], versican[116] activate DCs mediated by 
TLRs resulting in pro-inflammatory outcomes[117,118]. 
Heparan sulfate, TLR4 agonist stimulates DC activation 
and enhanced allostimulation in vitro[113]. Blocking 
heparan sulfate serum levels with alpha­1­antitrypsin 
reduced extent of graft vs host diseases in mice[119]. 
Biglycan is released from ECM during tissue damage 
or may be produced by inflammatory cells and activ­
ates DCs via TLR2/4[115], MyD88, TRIF as shown in 
myocardial matrix[120]. Chondroitin sulfate proteoglycans 
regulate immunity in the CNS[121]. Breakdown of long 
glycosaminoglycan HA resulting in the formation of small 
HA fragments activated skin DCs in a TLR4­mediated 
manner[122]. Another ECM component, tenascin C initiates 
TLR4­mediated DC activation and generation of TH17 
cells[85,86].
DC receptors that recognize collagen, a major con-
stituent of the ECM, may be activating (discoidin domain 
receptors[74,75], mannose family receptors, glycoprotein 
Ⅵ) or tolerogenic [CD305/leukocyte-associated Ig-like 
receptor 1 (LAIR-1)[123]]. LAIR-1 binds soluble adsorbed 
collagen (hydroxyproline in Gly-Pro-Hyp) and interferes 
with DC differentiation in an immunoreceptor tyrosine-
based inhibitory motifs -mediated manner[124]. LAIR-1 
may play an important role in maintaining homeostasis 
and has been shown to be upregulated on tumour-
associated DCs[125]. On the other hand, soluble adsorbed 
collagen types Ⅰ, Ⅱ, Ⅲ, ligands of osteoclast-associated 
receptor were shown to activate human monocyte­
derived DCs and triggered upregulation of maturation 
markers, TNF and TLR signalling demonstrating that ECM 
components can trigger DC activation locally, important 
in the context of DC differentiation into bone-degrading 
osteoclasts in the synovial tissues of rheumatoid arthritis 
patients[76].
INTellIGeNT bIOmaTeRIal DesIGN TO 
mImIC eCm IN TIssUe ReGeNeRaTION 
In recent years, tissue engineering strategies have 
been proposed to address the shortfall of utilizable 
donor tissues for transplantation. The main objective 
is to generate functional, viable tissue substitutes 
that are well-integrated long-term in a site-specific 
manner. Several regenerative medicine approaches 
are ECM-based and some include the use of processed 
whole tissues such as decellularized stroma or human 
amniotic membrane where the intrinsic mechanical 
and functional properties of the matrix can be exploited 
to promote tissue regrowth. Other strategies employ 
ECM­derived biopolymers from mammalian and other 
sources including collagen, fibrin, chitin and chitosan, 
taking advantage of the dynamic, flexible nature of 
these scaffolds in directing cellular engineering of skin, 
cartilage, bone and nerve[126]. As a next step, bio-
interactive implants comprising polymers coated with 
ECM proteins such as laminin, fibronectin, collagen or 
with grafted or tethered cell adhesive peptides have 
been proposed[127]. 
Overcoming the host immune/inflammatory res­
ponse remains a significant challenge to the long-
term success of ECM-based implants. Most of this work 
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addresses the effect of various biomaterials on the 
inflammatory response and particularly macrophage 
behaviour and its effects on the ECM. However, little 
work has been done on how biomaterials affect DC 
behaviour and function. Information is needed in this 
area since biomaterials may not only act as allo and 
xenoantigens but can directly behave like DAMPS 
(see Introduction) and thereby promote autoimmune 
responses through host tissue damage. Since tissue 
via the ECM tightly regulate DC homeostasis and 
inflammation, this directly impinges on how artificial 
matrices affect DC behaviour and hence the balance 
between immunogenicity and tolerance. Artificial 
stroma and their components may activate or suppress 
DCs, induce DC differentiation, promote or inhibit 
fibrosis or change DC interactions with other cells, 
e.g., other inflammatory cells or activate the adaptive 
immune response e.g. as an “autoimmune” response 
when human altered matrices are implanted in humans 
(or mouse into mouse, etc.). Studies have comp­
ared the individual effects of natural polymers on DC 
responses. Human monocytes differentiated to DCs 
in the presence of the natural, biocompatible polymer 
chitosan, a polysaccharide derived from the exoskeleton 
of crustaceans or cell walls of fungi, were activated to 
a pro-inflammatory state (higher CD86, TNF-α, IL-
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Class of component ECM component DC responses DC receptors Overall impact
Collagen Soluble collagen Ⅰ[74] Murine BMDC upregulated CD86, IL-12, 
antigen uptake
DDR2 Pro-inflammatory
Soluble collagen Ⅰ[75] Human MDDC increased IL-12p40, TNF-α, 
IFN-γ 
DDR2 Pro-inflammatory
Adsorbed collagen Ⅰ, Ⅱ, Ⅲ[76] Human MDDC increased maturation 
markers, pro-inflammatory cytokines, 
allostimulation
OSCAR Pro-inflammatory
Dermal hydrogel (laminin β3, 
collagen Ⅳ, Ⅶ)[77]
Decreased width of granulation tissue - Skin regeneration, anti-
infl.
Adsorbed fibronectin, collagen Ⅰ, 
gelatin, Matrigel[78]
Murine myeloid DC on Matrigel were less 
mature (maturation marker, cytokines, 
morphology)
Adhesion 
complexes 
(CD29, 
CD49a-f, 
CD41, CD51, 
CD61)
Differential effects 
– Matrigel less 
inflammatory vs 
collagen Ⅰ
Collagen-like motifs in complement 
C1q[124]
Inhibits MDDC differentiation,
TLR activity of pDC
LAIR-1 Anti-inflammatory 
Glycoproteins Pre-adsorbed laminin, fibronectin[79] Human MDDC remained immature 
(maturation marker, high endocytosis)
Mannose 
receptor, DC-
SIGN
Anti-inflammatory
Modified Arg-Gly-Asp (RGD) on 
fibrillin[80]
Murine pDC adherence, TGB-β secretion 
increased in systemic sclerosis model
Integrins Pro-fibrotic
Proteoglycans Heparan sulfate[113,119] DC maturation increased (morphology, 
costimulatory factors, T cell stimulation)
TLR4 Pro-inflammatory
In GVHD blocking HS with alpha-1-
antitrypsin limited alloreactive T cells 
- Pro-inflammatory
Chondroitin sulfate[121] Impact immunity in CNS pathologies - Pro- and anti-
inflammatory
DAMPs[111-113,117,118] Activate DC TLRs Pro-infl.
Non-proteoglycan 
polysaccharides
Hyaluronan[82] Increased hylauronan corresponds to 
decreased murine DC activation
- Anti-inflammatory 
(tumours)
Natural polymer hyaluronic 
acid[129,130]
Decreased DC maturation (maturation 
markers, cytokines, allostimulation)
- Anti-inflammatory
Modulators Secreted protein acidic and rich in 
cysteine[88]
Organization of germinal centres in LNs for 
TH17 by follicular DC 
- -
Thrombospondin-1[89] DC-derived thrombospondin inhibits 
resolution of inflammation
CD47, CD36 Anti-inflammatory
Enzymes Matrix metalloproteinases[90] Endogenous MMP-2 prime DC to TH2 (IL-
12p70)
- TH2 profile
Tissue transglutaminases[151] Influence DC activation (concentration-
dependant) 
- Pro- and anti-
inflammatory
Glycosylation 
modifications
Gut mucous[107] Decrease in DC activation by inhibition of 
NF-κB
Dectin-1, 
galectin-3 
Anti-inflammatory
Tissue matrix in skin thymus, 
trachea[109]
Steady state homeostasis MGL1+ 
MGL2+
Anti-inflammatory
Table 2  Dendritic cell interactions with extracellular matrix components
DC: Dendritic cell; ECM: Extracellular matrix; OSCAR: Osteoclast-associated receptor; DDR: Discoidin domain receptors; IL: Interleukin-4; TNF-α: 
Tumour necrosis factor-α; IFN-γ: Interferon-γ; LAIR-1: Leukocyte-associated Ig-like receptor 1; TLR: Toll-like receptor; MGL: Macrophage galactose/
N-acetylgalactosamine-specific C-type lectin.
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1β and lower IL­10 levels)[128]. Also, it was observed 
that while alginate and hyaluronic acid were less mat-
uring to DCs, the opposite effect was observed with 
chitosan or agarose[129,130], implying that specific ECM 
mimetics can have applications in vaccine delivery or 
in tissue engineering whether host immune responses 
are desired or not, as suggested in[129]. Surprisingly, 
regenerative medicine approaches to reconstruct heart 
valves using xenogeneic porcine or bovine collagen 
and elastin, did not induce human DC maturation (low 
CD83 expression and TNF-α secretion)[131]. Hydrogels 
fabricated from lyophilized constituents of porcine 
dermal ECM were coated onto polypropylene meshes 
as a means of reducing the inflammatory responses 
associated with these non-biodegradable materials. 
The presence of ECM hydrogels facilitated decreased 
recruitment of CD86+ CD68+ M1 macrophages by day 
14 post implantation in rats and decreased collagen type
Ⅰ deposition related to wound healing responses[132]. HA 
was electrospun into nanofibers to assist the adherence 
and survival of NIH­3T3 fibroblasts to mimic ECM 
properties to support cell adhesion[133]. 
ECM­based scaffolds have been developed to boost 
tissue repair and reconstruction. Since collagen is a 
major ECM component in most tissues, different strate-
gies have been employed to generate three dimensional 
fibrillary collagen matrices, including plastic compression 
of hydrated polymerized collagen and fluid expulsion, 
using contractile properties of activated fibroblasts, 
as discussed in[134]. Regenerative biomaterial scaffolds 
composed of clinical grade recombinant human collagen 
hydrogels crosslinked with water soluble carbodiimides 
have been fabricated to mimic the type Ⅰ and Ⅲ coll-
agens predominantly present in natural corneas that 
are crosslinked with glycosaminoglycans[135]. These ECM 
mimetics are cell free, chemically well characterized, 
resistant to biodegradation and mimic natural corneas 
in terms of optical and mechanical properties of 
corneas. They retained optical clarity in partial[136] or 
full-thickness[137] corneal transplants in animal models 
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Figure 4  CD11c+ dendritic cells are involved in the host response to transplanted hydrogels. CD11c+ DC were detected in re-epithelialized layers surrounding 
RHCIII hydrogels transplanted in murine corneas, 22 d post transplantation (A, B). CD11c+ dendritic cells infiltrated hydrogels transplanted into murine corneas as 
early as 6 h (C) or 24 h (D, E) after transplantation and showed a transformation in morphology from rounded immature DC to well-differentiated DC at the latter 
time point after interacting with the three dimensional crosslinked collagen matrix. Images were taken within the hydrogel in (C-E) as shown in the schematic. DAPI: 
Nuclear staining shown in blue; CD11c in magenta; DC: Dendritic cell.
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and promoted corneal cellular and nerve regrowth. 
ECM scaffolds have also been fabricated to elucidate 
mechanisms underlying cell-matrix interactions in 
physiologically relevant settings. DCs were recruited 
to murine corneas transplanted with RHCIII hydrogels 
and could be detected surrounding and within the 
artificial matrix, demonstrating their involvement 
in the host response (Figure 4)[138]. Also, RHCIII 
hydrogels implanted in murine corneas underwent 
remodelling by cellular and ECM components as part 
of the wound healing process (Figures 5 and 6)[138]. 
A three dimensional model composed of epithelial 
cells, fibroblasts generating ECM components such as 
tropoelastin, vimentin, collagen type Ⅳ and laminin and 
DCs was developed to recapture the complexity and 
architecture of DC interplay with lung tissue mucosa 
towards maintaining homeostasis[139]. Lung epithelial 
cells are no longer considered mere physical barricades 
against foreign allergens but key players in mediating 
DC responses and TH2 responses as reviewed in this 
paper[140].
Three dimensional ECM mimetics have shown 
promise in the transition from bench to bedside. Notably, 
RHCIII scaffolds were employed as partial thickness 
corneal transplants in a 4-year clinical study in 10 
patients and demonstrated minimal rejection, enhanced 
stability, epithelial, stromal cell and nerve regeneration 
(human allografts) (Figure 7)[141]. Remarkably, DCs were 
not recruited into transplanted RHCIII hydrogels but in 
contrast were present in donor human allografts[141]. In 
another study, bone substitute P-15 comprising bone 
mineral calcium phosphate and cell­interactive peptide 
of collagen typeⅠ acted as a promising alternative to 
allografts in its ability to repair non-union fractures 
as exhibited in a pilot clinical study with 22 patients, 
an example of an ECM mimetic that has successfully 
reached the bedside[142]. A randomized clinical trial with 
120 patients showed that natural tissues derived from 
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Re-epithelialized corneas
Hydrogel
Retro corneal membrane
Figure 5  Merged images showing the formation of dense retro-corneal membrane separating corneal hydrogel from lens and posterior areas of eye, 
shown on day 22 after transplantation of murine corneas with RHCIII hydrogels. Newly generated membrane exhibits presence of alpha smooth muscle actin, 
likely produced by myofibroblasts recruited during the wound healing process. Tissue ingrowths into the RHCIII hydrogel are evidence of active remodelling of the 
artificial matrix scaffold by immune/inflammatory cells and ECM components, towards long-term integration with natural tissue. DAPI: Nuclear staining shown in blue; 
Alpha smooth muscle actin in green; ECM: Extracellular matrix.
Retro corneal
membrane
Hydrogel 20 × 40 ×
A B
Figure 6  Murine corneas transplanted with RHCIII hydrogels stained positive for extracellular matrix constituent tenascin C in the retro-corneal membrane, 
a marker of epithelial to mesenchymal transition, indicative of active wound healing (A) and WEHI-164 murine fibrosarcoma cell line cultured with 5 ng/mL 
transforming growth factor-β1 for 48 h also produced tenascin C (positive control) (B). DAPI: Nuclear staining shown in blue; Tenascin C in yellow.
Day 22 post transplantation
Tenascin C, DAPI
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porcine small intestinal mucosa consisting mainly of 
collagen along with other macromolecules, active forms 
of basic fibroblast growth factor and TGF-β, enhanced 
healing[143]. While promising strides have been made, 
several challenges remain including gaining successful 
integration of scaffolds into host, retaining long-term 
stability and functionality and obtaining immune accep-
tance. Exploiting our knowledge of DC-ECM interactions 
would be an important way forward. 
CONClUsION
We have reviewed the body of evidence describing intera­
ctions between DCs and the ECM and the constantly 
changing role of the latter in directing DC responses 
in normal conditions vs in inflammation. These mecha­
nisms may be active or reactive. While they offer us a 
glimpse of the numerous ways that the ECM restrains 
DCs to play very precise, context­dependant roles, there 
are probably many more aspects as yet undiscovered. It 
is possible that the decisions made by individual tissues 
in allowing DC to enter and reside in them or not and 
how and why this changes when the tissue is under 
attack will offer important insights into optimal design of 
artificial stroma.
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